Canna~Fangled Abstracts

Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis.

By December 23, 2016No Comments
J Neuroimmunol. 2016 Dec 23. pii: S0165-5728(16)30274-0. doi: 10.1016/j.jneuroim.2016.12.009.
[Epub ahead of print]

Abstract

pm-2-site-207COR167, a novel CB2-selective high affinity agonist, was found to significantly inhibit, in a dose-dependent manner, the proliferation of both peripheral blood mononuclear cells and myelin basic protein-reactive T cell lines from normal healthy subjects and patients with relapsing-remitting multiple sclerosis (MS). In MS, a significantly higher inhibition was observed in patients on treatment with disease modifying drugs compared to those naive to treatment. The inhibitory activity of COR167 was exerted through a mixed mechanism involving atypical and incomplete shift of Th1 phenotype towards Th2 phenotype associated with slight reduction of IL-4 and IL-5 as well as strongly reduced levels of Th17-related cytokines. COR167 was also able to reduce in vitro migration of stimulated immunocompetent cells through human brain endothelium associated with a significant reduction of levels of several chemokines. These findings demonstrate that COR167 exerts potent immunomodulatory effects and confirm the cannabinoid CB2 receptor as a novel pharmacological target to counteract neuroinflammation.

KEYWORDS:

CB2 receptor; Cannabinoids; Multiple sclerosis; Neuroimmunomodulation; Neuroinflammation

PMID: 28041663
DOI: 10.1016/j.jneuroim.2016.12.009
[PubMed – as supplied by publisher]
twin memes II